請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74613
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學(Ming-Shyue Lee) | |
dc.contributor.author | Tzu-Yu Lo | en |
dc.contributor.author | 駱子瑜 | zh_TW |
dc.date.accessioned | 2021-06-17T08:45:46Z | - |
dc.date.available | 2024-08-26 | |
dc.date.copyright | 2019-08-26 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-06 | |
dc.identifier.citation | 1 Ouellette V, Cote MF, Gaudreault RC, Tajmir-Riahi HA, Berube G. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity. European journal of medicinal chemistry 2019; 179: 660-666.
2 Ministry of Health and Welfare 2016. 3 Rawla P. Epidemiology of Prostate Cancer. World journal of oncology 2019; 10: 63-89. 4 De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG. Premalignancy in Prostate Cancer: Rethinking What we Know. Cancer prevention research (Philadelphia, Pa) 2016; 9: 648-656. 5 Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathology 2000; 31: 578-583. 6 Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian journal of andrology 2009; 11: 57-67. 7 Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757. 8 Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer metastasis reviews 1989; 8: 98-101. 9 de Groot AE, Roy S, Brown JS, Pienta KJ, Amend SR. Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis. Molecular cancer research : MCR 2017; 15: 361-370. 10 Gloushankova NA, Zhitnyak IY, Rubtsova SN. Role of Epithelial-Mesenchymal Transition in Tumor Progression. Biochemistry Biokhimiia 2018; 83: 1469-1476. 11 Yang Y, Jiang Y, Xie D, Liu M, Song N, Zhu J et al. Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer. Respiratory research 2018; 19: 41. 12 Amend SR, Roy S, Brown JS, Pienta KJ. Ecological paradigms to understand the dynamics of metastasis. Cancer letters 2016; 380: 237-242. 13 Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ precision oncology 2018; 2: 4. 14 Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y et al. Role of tumor microenvironment in tumorigenesis. Journal of Cancer 2017; 8: 761-773. 15 Gkretsi V, Stylianou A, Papageorgis P, Polydorou C, Stylianopoulos T. Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. Frontiers in oncology 2015; 5: 214. 16 Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Advances in chronic kidney disease 2014; 21: 7-17. 17 Engelken J, Altmeyer M, Franklin R. The disruption of trace element homeostasis due to aneuploidy as a unifying theme in the etiology of cancer. bioRxiv 2014: 002105. 18 Pedersen SF, Stock C. Ion channels and transporters in cancer: pathophysiology, regulation, and clinical potential. Cancer research 2013; 73: 1658-1661. 19 Watkins S, Sontheimer H. Unique biology of gliomas: challenges and opportunities. Trends in neurosciences 2012; 35: 546-556. 20 Pardo LA, Gomez-Varela D, Major F, Sansuk K, Leurs R, Downie BR et al. Approaches targeting K(V)10.1 open a novel window for cancer diagnosis and therapy. Current medicinal chemistry 2012; 19: 675-682. 21 Boedtkjer E, Moreira JM, Mele M, Vahl P, Wielenga VT, Christiansen PM et al. Contribution of Na+,HCO3(-)-cotransport to cellular pH control in human breast cancer: a role for the breast cancer susceptibility locus NBCn1 (SLC4A7). International journal of cancer 2013; 132: 1288-1299. 22 Chen Y, Zhang S, Wang X, Guo W, Wang L, Zhang D et al. Disordered signaling governing ferroportin transcription favors breast cancer growth. Cellular signalling 2015; 27: 168-176. 23 Andersen AP, Moreira JM, Pedersen SF. Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philosophical transactions of the Royal Society of London Series B, Biological sciences 2014; 369: 20130098. 24 Bachmann M, Costa R, Peruzzo R, Prosdocimi E, Checchetto V, Leanza L. Targeting Mitochondrial Ion Channels to Fight Cancer. International journal of molecular sciences 2018; 19. 25 Andrews NC. Iron homeostasis: insights from genetics and animal models. Nature reviews Genetics 2000; 1: 208-217. 26 Winter WE, Bazydlo LA, Harris NS. The molecular biology of human iron metabolism. Laboratory medicine 2014; 45: 92-102. 27 De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nature reviews Molecular cell biology 2008; 9: 72-81. 28 Le Blanc S, Garrick MD, Arredondo M. Heme carrier protein 1 transports heme and is involved in heme-Fe metabolism. American journal of physiology Cell physiology 2012; 302: C1780-1785. 29 Rouault TA. The intestinal heme transporter revealed. Cell 2005; 122: 649-651. 30 Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nature reviews Drug discovery 2017; 16: 400-423. 31 Cheng Y, Zak O, Aisen P, Harrison SC, Walz T. Structure of the human transferrin receptor-transferrin complex. Cell 2004; 116: 565-576. 32 Serum transferrin receptor levels for the assessment of iron status and iron deficiency in populations. World Health Organization 2014. 33 Sipe DM, Murphy RF. Binding to cellular receptors results in increased iron release from transferrin at mildly acidic pH. The Journal of biological chemistry 1991; 266: 8002-8007. 34 Bali PK, Zak O, Aisen P. A new role for the transferrin receptor in the release of iron from transferrin. Biochemistry 1991; 30: 324-328. 35 van Renswoude J, Bridges KR, Harford JB, Klausner RD. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proceedings of the National Academy of Sciences of the United States of America 1982; 79: 6186-6190. 36 Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proceedings of the National Academy of Sciences of the United States of America 1983; 80: 2258-2262. 37 Muir RK, Zhao N, Wei J, Wang Y-h, Moroz A, Huang Y et al. Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Central Science 2019; 5: 727-736. 38 Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free radical biology & medicine 2002; 33: 1037-1046. 39 Hider RC, Kong X. Iron speciation in the cytosol: an overview. Dalton transactions (Cambridge, England : 2003) 2013; 42: 3220-3229. 40 Dunaief D, Cwanger A, Dunaief JL. Chapter 63 - Iron-Induced Retinal Damage. In: Preedy VR (ed). Handbook of Nutrition, Diet and the Eye. Academic Press: San Diego, 2014, pp 619-626. 41 Hilton RJ, David Andros N, Watt RK. The ferroxidase center is essential for ferritin iron loading in the presence of phosphate and minimizes side reactions that form Fe(III)-phosphate colloids. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 2012; 25: 259-273. 42 Zhang Y, Mikhael M, Xu D, Li Y, Soe-Lin S, Ning B et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxidants & redox signaling 2010; 13: 999-1009. 43 Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends in biochemical sciences 2016; 41: 274-286. 44 Carlomagno F. Ferritinophagy and Cell Cycle Control. Blood 2016; 128: SCI-20. 45 Tang M, Chen Z, Wu D, Chen L. Ferritinophagy/ferroptosis: Iron-related newcomers in human diseases. Journal of cellular physiology 2018; 233: 9179-9190. 46 Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nature cell biology 2014; 16: 1069-1079. 47 Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. The Journal of biological chemistry 2001; 276: 7806-7810. 48 Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788. 49 Van Zandt KE, Sow FB, Florence WC, Zwilling BS, Satoskar AR, Schlesinger LS et al. The iron export protein ferroportin 1 is differentially expressed in mouse macrophage populations and is present in the mycobacterial-containing phagosome. Journal of leukocyte biology 2008; 84: 689-700. 50 Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell metabolism 2005; 1: 191-200. 51 Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. The Journal of clinical investigation 2011; 121: 4880-4888. 52 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature reviews Clinical oncology 2018; 15: 234-248. 53 Thompson JW, Bruick RK. Protein degradation and iron homeostasis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2012; 1823: 1484-1490. 54 Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nature reviews Cancer 2013; 13: 342-355. 55 ASPEREN IAV, FESKENS EJM, BOWLES CH, KROMHOUT D. Body Iron Stores and Mortality due to Cancer and Ischaemic Heart Disease: A 17-Year Follow-Up Study of Elderly Men and Women. International Journal of Epidemiology 1995; 24: 665-670. 56 Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. International journal of cancer 1994; 56: 379-382. 57 Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Annals of epidemiology 2004; 14: 195-201. 58 Nelson RL. Iron and colorectal cancer risk: human studies. Nutrition reviews 2001; 59: 140-148. 59 Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. Journal of the National Cancer Institute 1985; 75: 81-84. 60 Milman N, Pedersen P, a Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Annals of hematology 2001; 80: 737-744. 61 Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF, Jr. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. International journal of cancer 1995; 60: 160-162. 62 Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology (Baltimore, Md) 2010; 51: 1311-1318. 63 Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel, Switzerland) 2018; 11. 64 Vela D, Vela-Gaxha Z. Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Experimental & molecular medicine 2018; 50: e436. 65 Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H et al. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer research 2015; 75: 2211-2221. 66 Naoum FA. Iron deficiency in cancer patients. Revista brasileira de hematologia e hemoterapia 2016; 38: 325-330. 67 Chio IIC, Tuveson DA. ROS in Cancer: The Burning Question. Trends in molecular medicine 2017; 23: 411-429. 68 Bystrom LM, Guzman ML, Rivella S. Iron and reactive oxygen species: friends or foes of cancer cells? Antioxidants & redox signaling 2014; 20: 1917-1924. 69 Coates TD, Carson S, Wood JC, Berdoukas V. Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Annals of the New York Academy of Sciences 2016; 1368: 95-106. 70 Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nature reviews Cancer 2014; 14: 709-721. 71 Murthy S, Ryan A, He C, Mallampalli RK, Carter AB. Rac1-mediated mitochondrial H2O2 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. The Journal of biological chemistry 2010; 285: 25062-25073. 72 Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. LNCaP model of human prostatic carcinoma. Cancer research 1983; 43: 1809-1818. 73 Camaschella C. Treating iron overload with hepcidin. Blood 2006; 107: 2595. 74 Schägger H. Tricine–SDS-PAGE. Nature Protocols 2006; 1: 16-22. 75 DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Science advances 2016; 2: e1600200. 76 Vela D. Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies. Frontiers in oncology 2018; 8: 547. 77 Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et Biophysica Acta (BBA) - General Subjects 2009; 1790: 702-717. 78 Lin C-C, Hsieh H-L, Shih R-H, Chi P-L, Cheng S-E, Chen J-C et al. NADPH oxidase 2-derived reactive oxygen species signal contributes to bradykinin-induced matrix metalloproteinase-9 expression and cell migration in brain astrocytes. Cell Communication and Signaling 2012; 10: 35. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74613 | - |
dc.description.abstract | 血清中鐵離子濃度的代謝異常是臨床上癌症病人常見的併發症,並且亦有文獻指出鐵離子的代謝和人類癌症的進程有很大的關係,然而迄今鐵離子的代謝對人類前列腺癌在進程與侵襲能力上的影響仍不清楚。因此在本篇研究當中,我們嘗試探尋鐵離子對於攝護腺癌細胞在細胞存活與侵襲能力上的影響。從生物資料庫的分析顯示預後較差的攝護腺癌病人擁有較低的運鐵素表現量。此外,在我們的研究結果中也發現能過量表達鐵調素的攝護腺癌細胞的細胞培養液亦能促進其他攝護腺癌細胞的侵襲能力,顯示鐵條素確實會促進人類癌細胞的移動能力。此外,從外加三價鐵離子的實驗中我們出乎意料地發現鐵離子會抑制攝護腺癌細胞的侵襲能力並降低細胞內活性含氧物的量,並且不論是鐵調素或三價鐵離子都不會對基質金屬蛋白酵素9有顯著的影響。經由這些實驗結果顯示調控鐵的賀爾蒙鐵調素可以促進攝護腺癌細胞的侵襲能力,而三價的鐵離子則是會降低細胞的移動與活性含氧物的量,這些結果都指出鐵調素所誘導引發的攝護腺癌細胞侵襲能力增加的現象可能是經由一個和鐵離子不相關的路徑所導致的。 | zh_TW |
dc.description.abstract | Dysregulation of iron levels in sera has been often observed in various cancer patients and has been proposed that alteration of iron metabolism may play an important role in human cancer progression. However, the involvement of iron metabolism in prostate cancer cell invasion and progression is still unclear. In this study, I addressed whether iron metabolism played a role in prostate cancer cell viability and invasion. The results from the bioinformatics analysis from a public database showed that the low expression level of ferroportin was associated with poor prognosis of human prostate cancer patients. Moreover, our results showed that the conditioned media of the hepcidin-overexpressing cells could increase prostate cancer cell invasion, suggesting that hepcidin can induce human cancer cell motility. On the other hand, the results unexpectedly showed that the treatment of ferric iron reduced prostate cancer cell invasion and the cellular level of ROS. Both hepcidin and ferric ion treatments had no significant effects on metalloproteinase 9. The results together indicate that iron-hormone hepcidin exhibits an induction effect on prostate cancer cell invasion, and ferric ion treatment reduces prostate cancer cell motility and ROS. The data suggest that hepcidin-induced prostate cancer cell invasion may be through an iron-independent pathway. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:45:46Z (GMT). No. of bitstreams: 1 ntu-108-R06442016-1.pdf: 2505368 bytes, checksum: 5113997debf5e69f8a423fab0d3c925b (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Contents
致謝 I 摘要 III Abstract IV Chapter 1 Introduction 1 1.1 Prostate cancer 2 1.2 Cancer metastasis 2 1.3 Tumor microenvironment 3 1.3.1 Trace elements in tumor microenvironment 3 1.4 Iron metabolism 4 1.4.1 Transferrin cycle in iron metabolism 6 1.4.2 The role of ferritin in iron metabolism 7 1.4.3 The role of hepcidin in iron metabolism 8 1.4.4 Iron metabolism in cancers 10 1.5 Research motivation 11 Chapter 2 Material and Methods 12 2.1 Materials 13 2.2 Methods 13 Chapter 3 Results 26 3.1 Relationship between iron metabolism and human prostate cancer prognosis. 27 3.2 Up-regulation of hepicidin in highly invasive C-81 LNCaP cells, compared to lowly invasive C-33 LNCaP cells. 28 3.3 Hepcidin to be a potent stimulator for prostate cancer cell invasion. 28 3.4 Effects of hepcidin on the storage level of iron in prostate cancer PC3 cells. 30 3.5 ROS levels in hepcidin-treated C-33 and c-81 LNCaP cells. 30 3.6 Involvement of gelatinolytic enzymes in hepcidin-treated prostate cancer cells. 31 3.7 Iron suppressed prostate cancer cell invasion. 31 3.8 Matrix metalloproteases may not be affected by the treatment of ferric ion. 32 3.9 Effect of ferric ion on the ROS in prostate cancer PC3 cells. 33 3.10 Hepcidin may increase prostate cancer cells invasion in alternative pathway unrelated to cellular iron level. 33 Chapter 4 Discussion 35 Chapter 5 Figures 40 Figure 1. Correlation between the expression levels of iron-regulated ferroportin and prostate cancer malignant. 41 Figure 2. Correlation between the expression levels of hepcidin and the capability of prostate cancer cell invasion in a prostate cancer cell progression model. 42 Figure 3. Establishment of stable pools of Hepcidin-overexpressing C-33 LNCaP cells and analysis of the effect of hepcidin on prostate cancer cell invasion and the protein level of ferritin. 44 Figure 4. Mechanisms may not contribution to invasion ability under high hepcidin condition. 46 Figure 5. Effect of ferric iron on the viability, invasion, the levels of ferritin protein expression, MMP9, and ROS levels in PC3- Luc2 cells. 48 Figure 6. The effect of knockdown ferroportin in PC3- Luc2 cells. 50 Figure 7. The hypothesized model for iron and hepcidin contribution to prostate cancer cells invasion. 52 Chapter 6 References 53 | |
dc.language.iso | en | |
dc.title | 探討鐵代謝在人類攝護腺癌細胞轉移中所扮演的角色 | zh_TW |
dc.title | Effect of iron metabolism on human prostate cancer cell metastasis | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 張富雄(Fu-Hsiung Chang) | |
dc.contributor.oralexamcommittee | 張智芬(Zee-Fen Chang),黃祥博,陳美州 | |
dc.subject.keyword | 攝護腺癌,鐵調素,鐵離子,侵襲能力, | zh_TW |
dc.subject.keyword | Prostate cancer,Hepcidin,Iron,Invasion, | en |
dc.relation.page | 61 | |
dc.identifier.doi | 10.6342/NTU201902580 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-06 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。